Ketamine for pain: An update of uses in palliative care

Eric E. Prommer

doi:10.1089/jpm.2011.0244

Ketamine for pain: An update of uses in palliative care

Eric E. Prommer

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

Ketamine is a lipophilic, general anesthetic. When given at subanesthetic doses, it also has been found to be an effective analgesic, with efficacy in cancer-associated neuropathic pain, ischemic pain, and regional pain syndromes. It can be administered orally, intravenously, subcutaneously, and topically, and interacts with several receptors important in pain management, most importantly the N-methyl-D aspartate (NMDA) receptor. Blockade of the NMDA receptor is associated with reversal of opioid tolerance. Ketamine is metabolized via cytochrome P450 3A4, although no significant interactions have been reported. Ketamine is considered one of the World Health Organization (WHO) essential drugs for the management of refractory pain.

Original language	English (US)
Pages (from-to)	474-483
Number of pages	10
Journal	Journal of Palliative Medicine
Volume	15
Issue number	4
DOIs	https://doi.org/10.1089/jpm.2011.0244
State	Published - Apr 1 2012

ASJC Scopus subject areas

General Nursing
Anesthesiology and Pain Medicine

Access to Document

10.1089/jpm.2011.0244

Cite this

@article{93c5c7175b014199a81e7784af63cf31,

title = "Ketamine for pain: An update of uses in palliative care",

abstract = "Ketamine is a lipophilic, general anesthetic. When given at subanesthetic doses, it also has been found to be an effective analgesic, with efficacy in cancer-associated neuropathic pain, ischemic pain, and regional pain syndromes. It can be administered orally, intravenously, subcutaneously, and topically, and interacts with several receptors important in pain management, most importantly the N-methyl-D aspartate (NMDA) receptor. Blockade of the NMDA receptor is associated with reversal of opioid tolerance. Ketamine is metabolized via cytochrome P450 3A4, although no significant interactions have been reported. Ketamine is considered one of the World Health Organization (WHO) essential drugs for the management of refractory pain.",

author = "Prommer, {Eric E.}",

year = "2012",

month = apr,

day = "1",

doi = "10.1089/jpm.2011.0244",

language = "English (US)",

volume = "15",

pages = "474--483",

journal = "Journal of Palliative Medicine",

issn = "1096-6218",

publisher = "Mary Ann Liebert Inc.",

number = "4",

}

TY - JOUR

T1 - Ketamine for pain

T2 - An update of uses in palliative care

AU - Prommer, Eric E.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Ketamine is a lipophilic, general anesthetic. When given at subanesthetic doses, it also has been found to be an effective analgesic, with efficacy in cancer-associated neuropathic pain, ischemic pain, and regional pain syndromes. It can be administered orally, intravenously, subcutaneously, and topically, and interacts with several receptors important in pain management, most importantly the N-methyl-D aspartate (NMDA) receptor. Blockade of the NMDA receptor is associated with reversal of opioid tolerance. Ketamine is metabolized via cytochrome P450 3A4, although no significant interactions have been reported. Ketamine is considered one of the World Health Organization (WHO) essential drugs for the management of refractory pain.

AB - Ketamine is a lipophilic, general anesthetic. When given at subanesthetic doses, it also has been found to be an effective analgesic, with efficacy in cancer-associated neuropathic pain, ischemic pain, and regional pain syndromes. It can be administered orally, intravenously, subcutaneously, and topically, and interacts with several receptors important in pain management, most importantly the N-methyl-D aspartate (NMDA) receptor. Blockade of the NMDA receptor is associated with reversal of opioid tolerance. Ketamine is metabolized via cytochrome P450 3A4, although no significant interactions have been reported. Ketamine is considered one of the World Health Organization (WHO) essential drugs for the management of refractory pain.

UR - http://www.scopus.com/inward/record.url?scp=84859796838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859796838&partnerID=8YFLogxK

U2 - 10.1089/jpm.2011.0244

DO - 10.1089/jpm.2011.0244

M3 - Review article

C2 - 22500483

AN - SCOPUS:84859796838

SN - 1096-6218

VL - 15

SP - 474

EP - 483

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

IS - 4

ER -

Ketamine for pain: An update of uses in palliative care

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this